INVESTORS

Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.

 

About Us

Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Mar 1, 2021

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the...

Feb 26, 2021

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its licensing agreement from North Carolina State University ("NC State") to include the...

Feb 25, 2021

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its investor relations efforts. RedChip is the leader...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons
  • SEC Filings
    View annual filings, quarterly filings and more
  • FAQ's
    Check out our frequently asked questions for more information
  • Events
    Upcoming and past investor related events and announcements
Investor Presentation

Hoth Therapeutics’ research and development activities are focused on creating novel therapies where an unmet medical need exists.

Download

Subscribe
Keep up to date on Hoth Therapeutics News. Simply fill out your email below and you will be added to our email alerts.
* Required Fields
Our Pipeline

Hoth Therapeutics’ research and development activities are focused on creating novel therapies where an unmet medical need exists.

Investor Contact

LR Advisors LLC

Email: investorrelations@hoththerapeutics.com

Phone: (678) 570-6791